Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Details)

v3.7.0.1
Segment Reporting (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Jun. 30, 2016
Segment Reporting Information [Line Items]          
Revenues - external customers $ 37 $ 379 $ 247 $ 673  
Revenues - intersegment 0 0 0 0  
Research and development 1,136 1,048 3,005 2,303  
General and administrative 2,837 2,403 7,657 5,509  
Operating loss (3,936) (3,072) (10,415) (7,139)  
Interest expense (481) (323) (1,447) (323)  
Interest and other income 12 10 53 26  
Consolidated net loss (4,405) (3,385) (11,809) (7,436)  
Total assets 40,698 50,665 40,698 50,665 $ 51,600
Fixed assets, net 25,794 25,775 25,794 25,775 25,574
Intangible assets, net 1,895 2,139 1,895 2,139 $ 2,092
Depreciation expense 337 261 987 263  
Amortization of intangible assets 88 92 264 274  
Intersegment Eliminations [Member]          
Segment Reporting Information [Line Items]          
Revenues - external customers 0 0 0 0  
Revenues - intersegment (644) (129) (1,645) (129)  
Research and development (369) (129) (968) (129)  
General and administrative (275) 0 (677) 0  
Operating loss 0 0 0 0  
Interest expense 0 0 0 0  
Interest and other income 0 0 0 0  
Consolidated net loss 0 0 0 0  
Total assets (12,555) (40) (12,555) (40)  
Fixed assets, net 0 0 0 0  
Intangible assets, net 0 0 0 0  
Depreciation expense 0 0 0 0  
Amortization of intangible assets 0 0 0 0  
iBio, Inc. [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Revenues - external customers 0 371 161 665  
Revenues - intersegment 283 0 695 0  
Research and development 1,033 951 2,733 2,192  
General and administrative 1,276 1,532 3,864 4,550  
Operating loss (2,026) (2,112) (5,741) (6,077)  
Interest expense 0 0 0 0  
Interest and other income 8 8 35 24  
Consolidated net loss (2,018) (2,104) (5,706) (6,053)  
Total assets 20,573 11,015 20,573 11,015  
Fixed assets, net 8 13 8 13  
Intangible assets, net 1,895 2,139 1,895 2,139  
Depreciation expense 1 2 3 4  
Amortization of intangible assets 88 92 264 274  
iBio CMO [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Revenues - external customers 37 8 [1] 86 8 [1]  
Revenues - intersegment 361 129 [1] 950 129 [1]  
Research and development 472 226 [1] 1,240 240 [1]  
General and administrative 1,836 871 [1] 4,470 959 [1]  
Operating loss (1,910) (960) [1] (4,674) (1,062) [1]  
Interest expense (481) (323) [1] (1,447) (323) [1]  
Interest and other income 4 2 [1] 18 2 [1]  
Consolidated net loss (2,387) (1,281) [1] (6,103) (1,383) [1]  
Total assets 32,680 39,690 [1] 32,680 39,690 [1]  
Fixed assets, net 25,786 25,762 [1] 25,786 25,762 [1]  
Intangible assets, net 0 0 [1] 0 0 [1]  
Depreciation expense 336 259 [1] 984 259 [1]  
Amortization of intangible assets $ 0 $ 0 [1] $ 0 $ 0 [1]  
[1] iBio CMO commenced operations in December 2015